[Federal Register Volume 59, Number 210 (Tuesday, November 1, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-26972]


[[Page Unknown]]

[Federal Register: November 1, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Prospective Grant of Co-Exclusive License; Vector With Multiple 
Target Response Elements Affecting Gene Expression

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice is in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
a co-exclusive world-wide license to practice the invention embodied in 
U.S. Patent Application SN 07/596,299 (CIP of 07/467,497) entitled 
``Vector With Multiple Target Response Elements Affecting Gene 
Expression'' to Targeted Genetics Corporation, of Seattle, Washington. 
The patent rights in this invention have been assigned to the United 
States of America.
    The prospective license will be royalty-bearing, will comply with 
the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7, and will be 
co-exclusive with one other party, Genetic Therapy, Inc. It is 
anticipated that this license will be limited to the field of use of 
gene therapy treatment for Acquired Immunodeficiency Syndrome (AIDS). 
Publication of this notice should be considered a modification of an 
earlier notice ``Prospective Grant Of Exclusive License: Vectors For 
Gene Therapy Treatment Of AIDS'' (Vol. 57, No. 169, Monday, August 31, 
1992, page 39405).
    This prospective co-exclusive license may be granted unless, within 
60 days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    The patent application describes the design and construction of DNA 
sequences that will inhibit viral replication through competitive 
inhibition of tat function and by down-regulating HIV-1 LTR-directed 
gene expression. Inhibition is mediated via the product of 
transcription of the newly constructed vector. The vector product is 
directed against the AIDS virus (HIV) and may be used in vaccine 
development (intracellular immunization) and as a therapeutic agent for 
treating viral infections. Unlike other similar vectors, this invention 
is not limited by retroviral mutations or by variations between 
different HIV isolates.

ADDRESSES: Requests for a copy of this patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Mr. Steven M. Ferguson, Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852. 
Telephone: (301) 496-7735 extension 266; Facsimile: (301) 402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent application(s). Applications for a license filed 
in response to this notice will be treated as objections to the grant 
of the contemplated license. Only written comments and/or applications 
for a license which are received by NIH on or before [insert date 60 
days after date of publication in the Federal Register] will be 
considered.

    Dated: October 24, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-26972 Filed 10-31-94; 8:45 am]
BILLING CODE 4140-01-P